Impact of Delayed Diagnosis in IBD on Clinical Outcomes and Healthcare Delivery

Background: Delays in diagnosis are unfortunately quite common in most health systems. It is apparent that timely diagnosis is more likely to have a favourable outcome. However, there may be many reasons why timely diagnosis is not always achieved. The aim of our study was to report on the impact of delays on IBD-related adverse outcomes (AOs). Methods: New patients referred for suspected IBD to a single tertiary care centre between January 2013 to December 2017 were identified using EMR. For purposes of the study, a cut-off time was set by investigators for each delay-type based on best average hospital waiting times. The reasons for delays in patient journey until start of treatment and data on pre-defined AOs (steroid & other rescue therapies, hospitalisations, surgery) were recorded for each patient until end of June 2021. The data were analysed using multiple Pearson correlations and Cox proportional Hazard model to determine whether there is a difference in survival without AOs between patients with and without a delay. Results: Total of 105 patients were identified using stringent criteria (M = 58; median age = 32 y) with a long median follow-up of 55 months. 65, 27 and 13 patients had final diagnosis of Ulcerative colitis, Crohn's disease and Unclassified colitis respectively, and analysed collectively. In our cohort, the longest delay-types noted were-patients seeking medical attention (median = 4 months; range 1 to 84 months), arranging gastroenterology clinic review after referral from primary care (median = 5 weeks; range 1 to 30 weeks), and waiting for index endoscopy (median = 3 weeks; 1 to 36 weeks). Patient stratification based on delay-type using specific cut-off times for each showed a statistically significant difference in survival without AOs for all (when comparing delay v/s no delay). Conclusions: In our cohort we report that delays, and subsequent untreated chronic inflammation, leads to poor outcomes in patients with newly diagnosed IBD regardless of whether delays are patient-related or health-system-related. Also, cumulative delays in the hospital appear to increase the use of biologics in consecutive years. Understanding these factors help rectify and offer long-term solutions.